The Irritable Bowel Syndrome Treatment Market Size was valued at USD 1.47 billion in 2022, and is expected to reach USD 2.81 billion by 2030, and grow at a CAGR of 8.4% over the forecast period 2023-2030.
Irritable bowel syndrome (IBS) is a prevalent chronic gastrointestinal condition affecting the colon. Gas, bloating, discomfort, constipation, and diarrhea are some of the symptoms of IBS. IBS is a chronic ailment that necessitates long-term treatment. IBS symptoms can be managed by making lifestyle and daily nutrition modifications, as well as addressing any stress. IBS has severe signs and symptoms in a limited number of patients who require therapy and counselling.
Get more information on Irritable Bowel Syndrome Treatment Market - Request Sample Report
Irritable bowel syndrome affects one out of every five Americans, but just a small percentage seek medical help. Irritable bowel syndrome is one of the most common GI disorders, despite being regarded as non-threatening. It affects about 12% of the population. IBS is more common in those under the age of 45 and is twice as common in women as it is in males. Rectal bleeding, weight loss, and severe abdominal pain at night are all serious symptoms of IBS.
DRIVERS
RESTRAINTS
OPPORTUNITIES
Type, product, end user, and geography are all segments of the irritable bowel syndrome therapy market. IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS are the three types of IBS on the market. Rifaximin, eluxadoline, lubiprostone, linaclotide, and other products make up the market. Hospital pharmacies, pharmacy stores and retail pharmacies, and online pharmacies are the three types of pharmacies that exist.
By Type
IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS are the three categories in which the market is divided. In 2018, the IBS-D (irritable bowel syndrome with Diarrhea) segment dominated the irritable bowel syndrome therapy market. Moreover, this segment is projected to expand at the fastest rate during the forecast period, owing to an increase in the prevalence of gastrointestinal diseases like constipation and diarrhea as a result of changing lifestyles, a rise in the geriatric population, a surge in the uptake of drugs like linaclotide and lubiprostone, and an increase in patient awareness of the treatment of irritable bowel syndrome.
By Product
The rifaximin segment generated the most revenue, and this trend is likely to continue throughout the forecast period. This is due to the rise in the prevalence of irritable bowel syndrome, a surge in the adoption of irritable bowel syndrome products, an increase in the geriatric population, increased awareness of irritable bowel syndrome and improved diagnosis, and the development of technologically advanced treatment products, which has fueled the demand for irritable bowel syndrome treatment market products globally.
By Type
By Product
By End User
.png)
Need any customization research on Irritable Bowel Syndrome Treatment Market - Enquiry Now
Asia-Pacific offers significant potential for key participants in the irritable bowel syndrome treatment market, with rising awareness of irritable bowel syndrome therapy and product uptake. Furthermore, developments in healthcare infrastructure, an increase in the number of hospitals with advanced medical facilities, a growing R&D sector, rising healthcare reforms, and technical advancements in the field of healthcare all contribute to market growth. Other factors like leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, a large population base, and high disposable incomes are expected to fuel the growth of the Asia-Pacific irritable bowel syndrome treatment market.
REGIONAL COVEREGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Some of the major key players are as follows: Allergan plc, Synergy Pharmaceuticals, Inc, Abbott, Sucampo Pharmaceuticals, Inc., Ardelyx, Inc., Bausch Health, Novartis AG, Astellas Pharma Inc, and other players.
| Report Attributes | Details |
|---|---|
| Market Size in 2022 | US$ 1.47 Billion |
| Market Size by 2030 | US$ 2.81 Billion |
| CAGR | CAGR of 8.4% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (IBS with Diarrhea (IBS-D), Mixed-presentation IBS (IBS-M), IBS with Constipation (IBS-C)) • By Product (Eluxadoline, Lubiprostone, Rifaximin, Linaclotide, Others) • By End User (Drug Stores & Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Allergan plc, Synergy Pharmaceuticals, Inc, Abbott, Sucampo Pharmaceuticals, Inc., Ardelyx, Inc., Bausch Health, Novartis AG, Astellas Pharma Inc, and other players. |
| DRIVERS | • Anxiety is on the rise • There is a robust drug pipeline to combat it • Depression is also on the rise. |
| RESTRAINTS | • Government regulations that are extremely strict • Patients are dissatisfied with the IBS treatment they are receiving. |
Irritable Bowel Syndrome Treatment market is expected to grow at a CAGR of 8.4% over the forecast period 2022-2030.
Government regulations that are extremely strict, and Patients are dissatisfied with the IBS treatment they are receiving are the restraints of the Irritable Bowel Syndrome Treatment.
Irritable Bowel Syndrome Treatment Market is divided into three segments and they are By Type, By Product, By End User
Asia-Pacific offers significant potential for key participants in the irritable bowel syndrome treatment market, with rising awareness of irritable bowel syndrome therapy and product uptake.
The rifaximin segment generated the most revenue, and this trend is likely to continue throughout the forecast period.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Irritable Bowel Syndrome Treatment Market Segmentation by Type
8.1 IBS with Diarrhea (IBS-D)
8.2 Mixed-presentation IBS (IBS-M)
8.3 IBS with Constipation (IBS-C)
9. Irritable Bowel Syndrome Treatment Market Segmentation, by Product
9.1 Eluxadoline
9.2 Lubiprostone
9.3 Rifaximin
9.4 Linaclotide
9.5 Others
10. Irritable Bowel Syndrome Treatment Market Segmentation by End User
10.1 Drug Stores & Retail Pharmacies
10.2 Hospitals Pharmacies
10.3Online Pharmacies
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 USA
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 South Korea
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.1 Israel
11.5.2 UAE
11.5.3 South Africa
11.5.4 Rest
11.6 Latin America
11.6.1 Brazil
11.6.2 Argentina
11.6.3 Rest of Latin America
12 Company Profiles
12.1 Allergan plc.
12.1.1 Financial
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Synergy Pharmaceuticals, Inc.
12.3 Abbott
12.4 Sucampo Pharmaceuticals, Inc.
12.5 Ardelyx, Inc.
12.6 Bausch Health
12.7 Novartis AG
12.8 Astellas Pharma Inc.
13 Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share Analysis
13.3 Recent Developments
14 Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Operating Room Management Market Size was valued at USD 2.80 billion in 2023, and is expected to reach USD 7.06 billion by 2031 and grow at a CAGR of 12.24% over the forecast period 2024-2031.
The Injectable Cytotoxic Drugs Market size was USD 19.58 Billion in 2023 and is expected to Reach USD 38.15 Billion by 2032 and grow at a CAGR of 6.9% over the forecast period of 2024-2032.
The AI In Medical Imaging Market was USD 1.76 billion in 2023 and is expected to Reach USD 23.65 billion by 2032 and grow at a CAGR of 33.48% over the forecast period of 2024-2032.
The Regenerative Medicine Market was estimated at USD 15.99 billion in 2023 and is poised to reach 96.53 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 25.2% for the forecast period of 2024-2031.
The Asthma Treatment Market Size was valued at USD 26.7 billion in 2023, and is expected to reach USD 42.13 billion by 2032, and grow at a CAGR of 5.2% over the forecast period 2024-2032.
The Biodegradable Medical Plastics Market Size was valued at USD 1.7 Bn in 2023 and will reach USD 4.5 Bn by 2032 and grow at a CAGR of 11.5% Over the Forecast Period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
